Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

A three-drug combination to treat BRAF-mutant cancers

Nature Medicine volume 23, pages 913–914 (2017)Cite this article

Subjects

A new study that uses a triple-drug combination to overcome a major mechanism of drug resistance in cancer provides insights into the evolutionary paths taken by tumors in the face of selective pressure.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Sequential inhibition of BRAF pathway components is at a lower fitness threshold than simultaneous inhibition.

References

  1. Pratilas, C.A., Xing, F. & Solit, D.B. Curr. Top. Microbiol. Immunol. 355, 83–98 (2010).

    Google Scholar 

  2. Shi, H. et al. Nat. Commun. 3, 724 (2012).

    Article  Google Scholar 

  3. Larkin, J. et al. N. Engl. J. Med. 371, 1867–1876 (2014).

    Article  Google Scholar 

  4. Long, G.V. et al. N. Engl. J. Med. 371, 1877–1888 (2014).

    Article  Google Scholar 

  5. Xue, Y. et al. Nat. Med. 23, 929–937 (2017).

    Article  CAS  Google Scholar 

  6. Bock, C. & Lengauer, T. Nat. Rev. Cancer 12, 494–501 (2012).

    Article  CAS  Google Scholar 

  7. Brioli, A., Melchor, L., Cavo, M. & Morgan, G.J. Br. J. Haematol. 165, 441–454 (2014).

    Article  Google Scholar 

  8. Das Thakur, M. et al. Nature 494, 251–255 (2013).

    Article  CAS  Google Scholar 

  9. Skoulidis, F. & Papadimitrakopoulou, V.A. Clin. Cancer Res. 23, 618–622 (2017).

    Article  CAS  Google Scholar 

  10. Holderfield, M., Nagel, T.E. & Stuart, D.D. Br. J. Cancer 111, 640–645 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Calico Life Sciences, South San Francisco, California, USA

    Ari J Firestone & Jeff Settleman

Authors
  1. Ari J Firestone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeff Settleman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeff Settleman.

Ethics declarations

Competing interests

A.J.F. and J.S. are both employees of Calico Life Sciences.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Firestone, A., Settleman, J. A three-drug combination to treat BRAF-mutant cancers. Nat Med 23, 913–914 (2017). https://doi.org/10.1038/nm.4382

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.4382

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer